Calcitonin intranasal - Unigene

Drug Profile

Calcitonin intranasal - Unigene

Alternative Names: Fortical Intranasal; Nasal calcitonin - Unigene; Recombinant salmon calcitonin intranasal; Salcatonin intranasal - Unigene; sCT nasal

Latest Information Update: 18 Mar 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unigene Laboratories
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin receptor agonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Postmenopausal osteoporosis

Most Recent Events

  • 11 Mar 2013 The US FDA Advisory Committe concludes that the benefits of calcitonin products do not outweigh the risks, and should not continue to be broadly marketed
  • 07 Jun 2011 Unigene terminates its involvement in Unigene Biotechnology (the China Joint Venture) and recovers all intellectual property rights granted under the agreement with Shijiazhuang Pharmaceutical Group
  • 03 Apr 2008 Phase-III clinical trials in Postmenopausal osteoporosis (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top